PL-100

• Description :

  PL-100 is a potent HIV-1 protease inhibitor with a Ki of 36 pM and an EC50 of 16 nM. PL-100 inhibits viral replication by suppressing HIV-1 protease activity and demonstrates excellent antiviral efficacy against drug-resistant HIV strains. PL-100 can be used in research on drug-resistant HIV disease[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  HIV Protease

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Metabolic Enzyme/Protease

• Field of Research :

  Infection; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/pl-100.html

• Smiles :

  O=S(N(CC(C)C)[C@H](CO)CCCCNC([C@@H](NC(OC)=O)C(C1=CC=CC=C1)C2=CC=CC=C2)=O)(C3=CC=C(C=C3)N)=O

• Molecular Formula :

  C33H44N4O6S

• Molecular Weight :

  624.79

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

• References & Citations :

  [1]Dandache S, et al. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51 (11) :4036-43.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [612547-11-2]